Q1 Earnings Forecast for OmniAb Issued By HC Wainwright

OmniAb, Inc. (NASDAQ:OABI) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for OmniAb in a research note issued on Wednesday, March 19th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.15) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.57) EPS, FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at ($0.27) EPS.

Separately, Benchmark decreased their price objective on shares of OmniAb from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, March 20th.

OmniAb Price Performance

OmniAb stock opened at $2.54 on Monday. OmniAb has a fifty-two week low of $2.23 and a fifty-two week high of $5.63. The firm’s 50 day simple moving average is $3.33 and its 200-day simple moving average is $3.75. The company has a market cap of $358.69 million, a P/E ratio of -4.10 and a beta of -0.14.

OmniAb (NASDAQ:OABI) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. The firm had revenue of $10.80 million for the quarter, compared to the consensus estimate of $10.13 million. During the same quarter in the previous year, the company earned ($0.14) EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Hsbc Holdings PLC acquired a new stake in shares of OmniAb during the 4th quarter valued at about $38,000. Choreo LLC bought a new position in OmniAb during the fourth quarter valued at approximately $41,000. Rangeley Capital LLC acquired a new stake in OmniAb in the fourth quarter valued at approximately $41,000. KLP Kapitalforvaltning AS acquired a new stake in OmniAb in the fourth quarter valued at approximately $49,000. Finally, Walleye Capital LLC bought a new stake in OmniAb in the third quarter worth approximately $61,000. Hedge funds and other institutional investors own 72.08% of the company’s stock.

Insiders Place Their Bets

In other OmniAb news, CFO Kurt A. Gustafson sold 7,255 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $3.67, for a total value of $26,625.85. Following the completion of the sale, the chief financial officer now owns 206,211 shares in the company, valued at $756,794.37. This represents a 3.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Matthew W. Foehr sold 13,964 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $3.68, for a total transaction of $51,387.52. Following the transaction, the chief executive officer now owns 3,798,682 shares in the company, valued at approximately $13,979,149.76. This represents a 0.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 112,260 shares of company stock worth $376,601. 8.60% of the stock is currently owned by company insiders.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.